Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories To Announce Second Quarter 2003 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--June 30, 2003--Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2003 financial results on Tuesday, July 29, 2003, after the market closes. A conference call has been scheduled to discuss the results on Wednesday, July 30, 2003, at 8:30 a.m. Eastern Daylight Time.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. To listen to the webcast, please go to the website at any time before the call but at least fifteen minutes prior, to register, download, and install any necessary audio software. For those who cannot listen to the live webcast, a replay will be accessible through the website approximately two hours following the conference call and will remain available until Wednesday, August 6, 2003.

Charles River Laboratories, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies. The Company also offers a broad and growing portfolio of biomedical products and services that enable customers to reduce cost, increase speed, and enhance productivity and effectiveness in drug discovery and development. Charles River's customer base spans over 50 countries, and includes all of the major pharmaceutical companies, biotechnology companies, and many leading hospitals and academic institutions. The Company operates 82 facilities in 16 countries worldwide. For more information, visit the Company's web site at http://www.criver.com.


    CONTACT: Investor Relations Contact:
             Charles River Laboratories
             Susan E. Hardy, 978/658-6000 ext.1616

    SOURCE: Charles River Laboratories

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)